Novo Nordisk A/S

Novo Nordisk A/S (NYSE: NVO) is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Recent Business and Financial Updates

• First Half 2025 Financial Performance: Novo Nordisk reported robust financial results for the first six months of 2025, with sales increasing by 18% at constant exchange rates (CER) to DKK 133.2 billion and operating profit growing by 29% at CER to DKK 67.6 billion. This performance was bolstered by a DKK 3 billion gross-to-net sales adjustment related to prior years, including a 340B provision in Q2 2025, though partially offset by the ocedurenone impairment from Q2 2024 and costs associated with the acquisition of three Catalent manufacturing sites. The company achieved a diluted earnings per share of DKK 12.49, reflecting strong operational efficiency. Sales growth was driven by a 65% increase in Obesity care sales, particularly for Wegovy®, and an 11% rise in GLP-1 diabetes sales, led by Ozempic®, despite competitive pressures in the U.S. market.
• Updated 2025 Financial Outlook: On July 29, 2025, Novo Nordisk revised its full-year 2025 outlook, projecting sales growth of 8-14% at CER, down from the May 7, 2025, forecast of 13-21%, and operating profit growth of 10-16% at CER, reduced from 16-24%. This adjustment reflects lower-than-expected growth for Wegovy® in the U.S. obesity market and Ozempic® in the U.S. GLP-1 diabetes market, driven by persistent use of compounded GLP-1s, slower market expansion, and increased competition. Sales and operating profit growth in Danish kroner are expected to be 4 and 7 percentage points lower than at CER, respectively, primarily due to the depreciation of the USD/DKK exchange rate. The company also anticipates a financial items net gain of DKK 3 billion, mainly from hedged currency gains, and free cash flow of DKK 35-45 billion, impacted by lower volume growth of GLP-1 treatments in the U.S.
• Strategic Response to Market Challenges: Novo Nordisk is addressing challenges in the U.S. market, particularly the continued prevalence of unsafe and unlawful compounded GLP-1 drugs, despite the FDA’s grace period for mass compounding ending on May 22, 2025. The company is pursuing litigation and other strategies to protect patients from knockoff semaglutide drugs, which have hindered Wegovy® penetration, particularly in the cash channel, where NovoCare® Pharmacy and retail prescriptions totaled approximately 31,000 weekly prescriptions. Novo Nordisk is intensifying direct-to-patient initiatives, including expanding NovoCare® Pharmacy and telehealth collaborations, to enhance access to branded GLP-1 treatments. Additionally, the company expects a positive impact from Wegovy® being the only GLP-1 medicine covered for obesity in the CVS national template formulary, effective July 1, 2025.
• Research and Development Progress: In research and development, Novo Nordisk completed the REDEFINE 2 trial for CagriSema, demonstrating a 15.7% weight loss in adults with obesity or overweight and type 2 diabetes, with plans to file for regulatory approval in Q1 2026. The company also submitted oral semaglutide 25 mg for obesity and once-weekly semaglutide 2.4 mg for MASH to the U.S. FDA, with the latter granted priority review. These advancements underscore Novo Nordisk’s commitment to innovation in obesity and diabetes care, aiming to maintain its leadership in the GLP-1 market despite competitive and regulatory challenges.
• Financial Stability and Global Expansion: Novo Nordisk’s financial stability is supported by its strong performance in International Operations, which grew 19% at CER in Q1 2025, and continued global rollout of Wegovy® to address the unmet needs of approximately 1 billion people living with obesity. The company’s cost management efforts, including reduced spending to offset lower sales expectations, and a high Gross Retention Rate contribute to its resilience. However, the acquisition of Catalent sites introduces a mid-single-digit negative impact on operating profit growth. With a comprehensive strategy to combat compounding, expand market access, and advance its R&D pipeline, Novo Nordisk is well-positioned to navigate market dynamics and sustain long-term growth in the global pharmaceutical industry.

Technical Observation (on the daily chart):

The Relative Strength Index (RSI) over a 14-day period stands at a value of 26.57, currently downward trending and inside oversold zone, with expectations of a consolidation or a upward momentum if the important support of USD 50-USD 55 holds. Additionally, the stock's current positioning is below both the 50-period SMA and 200-period SMA, which may serve as dynamic short to medium-term resistance levels.

Novo Nordisk A/S delivered robust financial performance in the first half of 2025, achieving an 18% sales increase to DKK 133.2 billion and a 29% operating profit growth to DKK 67.6 billion at constant exchange rates (CER), driven by strong demand for its GLP-1-based treatments, including a 65% surge in Obesity care sales led by Wegovy® and an 11% rise in Ozempic® sales. Despite revising its full-year 2025 outlook to a more cautious 8-14% sales growth and 10-16% operating profit growth at CER due to U.S. market challenges from compounded GLP-1s and competition, the company is actively addressing these through litigation, expanded direct-to-patient initiatives like NovoCare® Pharmacy, and a favorable CVS formulary position for Wegovy®. Bolstered by significant R&D advancements, such as the successful REDEFINE 2 trial for CagriSema and regulatory submissions for oral semaglutide and MASH indications, alongside a projected DKK 3 billion financial items gain and DKK 35-45 billion in free cash flow, Novo Nordisk’s strategic focus on innovation and global expansion positions it as a compelling investment opportunity in the pharmaceutical sector. 

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Buy’ rating has been given to Novo Nordisk A/S (NYSE: NVO) at the current market price of USD 54.16, as of July 29, 2025, at 09:50 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is July 29, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.